Figure 1.
ICC staining of FZD3 in (A) CRC, (B), CAD, (C) colorectal polyp, (D) normal colorectal tissues, (E) positive control and (F) negative control (Original magnification, X400, scale bar = 100 µm).
Figure 2.
ICC scores of FZD3 in (A) CRC, (B) CAD, (C) colorectal polyp and (D) normal colorectal tissues.
Figure 3.
ICC scores of FZD3 in various Dukes stage of patients with CRC.
Figure 4.
ICC staining of FZD3 in (A) a lymph node with CRC metastasis from a Dukes 3 patient and (B) an ovary with CRC metastasis from a Dukes 4 patient (T = tumor, Lym = lymphoid cells, original magnification, X400, scale bar = 100 µm).
Figure 5.
FZD3 expression in various non-CRC metastatic carcinomas.
(A) Percentage of various non-CRC metastatic carcinomas with FZD3 ICC staining and (B) ICC scores of FZD3 in various non-CRC metastatic carcinomas. (HCC = hepatocellular carcinoma, RCCC = renal clear cell carcinoma, SCC1 = squamous cell carcinoma, LAC = lung adenocarcinoma, LNSCC = lung non-small cell carcinoma, PTC = papillary thyroid carcinoma, BC = breast carcinoma, OCCC = ovary clear cell carcinoma, CNSCC = cervical non-small cell carcinoma, FTSAC = fallopian tube serous adenocarcinoma, TCC = transitional cell carcinoma, SCC2 = small cell carcinoma and CND = carcinoma with neuroendocrine differentiation).
Figure 6.
ICC staining of FZD3 in (A) a metastatic hepatocellular carcinoma and (B) a metastatic renal clear cell carcinoma (Original magnification, X400, scale bar = 100 µm).
Figure 7.
ICC scores of FZD3 in (A) adenomas with synchronous carcinomas (AWSC) and (B) pure adenomas.
Figure 8.
Overall survival analyses for the 1st cohort of 186 Dukes A to D CRC patients (A) stratified by a median FZD3 ICC score of 327, (B) with high and low FZD3 expression and (C) with moderately high and moderately low FZD3 expression.